<DOC>
	<DOCNO>NCT00000863</DOCNO>
	<brief_summary>To evaluate efficacy WR 6026 daily treatment mild PCP . To evaluate safety tolerance WR 6026 . To assess correlation plasma WR 6026 concentration outcome/toxicity .</brief_summary>
	<brief_title>A Study WR 6026 Treatment Pneumocystis Carinii Pneumonia ( PCP ) HIV-Infected Patients</brief_title>
	<detailed_description>All patient receive initial load dose WR 6026 , follow next morning morning thereafter 1 2 low dos WR 6026 take fast state 3 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Any medication list exclude permitted study . [ AS PER AMENDMENT 4/11/97 : PCP prophylaxis permit initiated Day 21 evaluation complete . ] Patients must : Documented HIV infection . Documented PCP . On room air ABG , PO2 value great equal 70 mm Hg ( Aa ) DO2 le 35 mm Hg . Signed informed consent parent legal guardian patient le 18 year age . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known hypersensitivity quinolines . If patient unwilling unable discontinue medication antiPCP activity treatment period study . Concurrent Medication : Excluded : Any patient unwilling unable discontinue medication antiPCP activity treatment period study ( e.g. , TMP/SMX , sulfonamide , dapsone , pentamidine , trimetrexate , atovaquone , clindamycin , azithromycin , pyrimethamine , primaquine ) . Methemoglobinemiaproducing agent ( dapsone , primaquine , sulfonamide , chloroquine , nitrofurantoin , nitrate nitrite ) . Patients follow prior condition symptom exclude : History G6PD deficiency , hemoglobin M abnormality , NAD methemoglobin reductase deficiency . Prior Medication : Excluded : More 24 hour receipt antiPCP treatment current episode PCP . Receipt prior PCP prophylaxis permit , long discontinue study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>WR 6026</keyword>
</DOC>